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Abstract: Wound biology is complex. Wounds which were until recently seen only as defects in tissues are now increasingly
interpreted in cellular and molecular terms. Growth factors, cytokines, proteases and adhesion molecules which participate in wound
healing are discussed in this article. From a clinical perspective, conceptual shifts of importance, including moist wound healing,
wound bed preparation and wound assessment, are presented. The frontiers of therapeutics employed in wound healing continue to
advance with an increasing array of modalities joining the ranks at a regular pace. A range of currently available as well as evolving
therapies– physical (topical negative pressure therapy, warming, electrical stimulation), biological (larva therapy, skin substitutes,
stem cell therapy, growth factors, gene therapy) and of a miscellaneous variety (hyperbaric oxygen, dressings)– are appraised.
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Introduction
A healing wound is an extremely complex and dynamic
tissue which in some ways could be regarded as an organ,
albeit a temporary one. Scientific enquiry into the many
facets of wound healing is far from complete and
consequently the knowledge base is continually being
enriched by input, as much from the clinician at the
bedside, as the researcher’s bench.
Increasing clarity in definitions, a systematic approach
to research, an organised and multi-professional
approach to management, and a willingness to consider
the patient’s perspective are some of the important
changes that have paralleled technological advances and
expertise, which, as ever, have been the prime drivers of
progress.
This article provides an overview which reflects on
some of the developments in cutaneous wound healing
over the last couple of decades that have either changed
or are likely to change the way wounds are understood,
evaluated and treated. In keeping with the generalist
theme of the article, discussion on specialised areas of
wound healing like scar management and issues relating
to specific problems like pressure ulcers have not been
addressed.

The conceptual advances pertaining to wound healing
will be outlined first, followed by a discussion on advances
in wound assessment. Finally the therapeutic advances
will be considered.
Conceptual advances in wound healing
Advances from a molecular perspective
Normal wound healing occurs in recognisable, usually
progressive, though overlapping, phases: the
haemostatic/inflammatory phase, the proliferative/cellular
phase and the remodelling phase. Giant strides have been
made in the understanding of wound healing at the
molecular level by the discovery of many families of
molecules which have provided insights into the
multitude of steps and interactions involved in each of
these phases.
Wound healing is a collaborative process involving a
variety of cells and matrix components which need to
interact continually towards a common goal. Growth
factors, cytokines, proteases and adhesion molecules,
which are discussed here, are but a few examples of
substances by which cells conduct a molecular talk and
engage in interactive cascades. In addition, it is
increasingly becoming clear that important regulatory
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roles are played by systems as diverse as the plasmin
cascade and nitric oxide.
Growth factors and cytokines
Growth factors and cytokines are 2 distinct categories
of signalling proteins that modulate wound healing at a
molecular and cellular level. However, in certain instances
the distinction may be blurred and some mediators like
PDGF, TGF β and TNF α straddle the divide.
Growth factors are constitutively present, usually
released by a few selected subsets of cells and have a

primarily trophic effects on cells. However, they may
indirectly influence inflammatory processes. Platelet
derived growth factor (PDGF), vascular endothelial growth
factor (VEGF), epidermal growth factor (EGF), fibroblast
growth factor (FGF), connective tissue growth factor
(CTGF), and transforming growth factor (TGFβ), along
with insulin-like growth factor (IGF) and colony stimulating
factors (granulocyte-G-CSF; granulocyte/ macrophage- GMCSF; macrophage-M-CSF) are amongst the key growth
factors in wound healing. A summary of the profiles of a
few selected growth factors is given in Table 1.

Table1. Profile of selected growth factors of importance in wound healing.

Growth factor

Physiological effects

Clinical and experimental correlates

TGFβ
Transforming growth factor
[β1, β2, β3 isoforms]

• Chemotactic to fibroblasts, monocytes,
macrophages,
lymphocytes
• Proliferation of epithelial cells, macrophages, lymphocytes,
fibroblasts
• Stimulates keratinocyte migration
• Induces expression of Pro- MMP-9 in keratinocytes
• Induces fibroblasts to secrete TIMPs
• Augments cell adhesion to matrix proteins by modulating
integrin receptor
• Stimulates fibroblasts to contract collagen matrix

Chronic wound fluid contains lower TGFβ
when compared to acute wounds

Scarless healing in the embryo has been
attributed to an absence of TGFβ

PDGF
Platelet derived growth factor

•
•
•
•
•

KGF
Keratinocyte growth factor
[KGF-1, KGF-2]

• Potent mediator of keratinocyte proliferation which under the
influence of KGF 2, upregulates the expression of many genes
• Stimulates keratinocyte and fibroblast motility

Trials of topical application underway

VEGF
Vascular endothelial
factor

• Potent angiogenic factor

VEGF administration improves granulationtissue formation
Potential being explored in salvage of
ischaemic flaps and in tissue expansion

• Directs epithelialisation in an autocrine fashion
• Stimulates fibroblast collagenase secretion
• Inhibits foetal wound contraction

Aged dermal fibroblasts have a decreased
EGF-receptor expression
EGF may contribute to the scarless repair
seen in utero

growth

EGF
Epidermal growth factor
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Neutrophil, monocyte, lymphocyte chemotaxis
Monocyte maturation
Potentiates VEGF production
Stimulates MMP production by fibroblasts
Stimulates myofibroblasts to contract matrix collagen

While higher concentrations of TGFβ1 and
TGFβ2 are associated with hyperfibrotic
disorders
TGFβ3 has been found to reduce scarring

First growth factor to be licensed for
topical therapy
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Cytokines are small molecular weight mediators which
primarily have a variable effect on inflammatory
processes by their influence on the cells of the immune
system. They may be released by practically all nucleated
cells, are expressed transiently and locally and elicit
varying responses in different cells. A summary of the
profiles of a few selected cytokines is given in Table 2.
Proteases and their inhibitors
Matrix metalloproteinases (MMPs) are a large family
of about 24 mammalian endopeptidases that play a
crucial role in wound healing. There are 4 collagenases, 2

gelatinases, 2 matrilysins, 3 stromelysins, 6 membrane
type MMPs and a miscellaneous group of 7 enzymes.
Remodelling of the extracellular matrix, which is an
important step in a number of stages in wound healing
like cell migration, angiogenesis and wound contraction,
is dependant on the MMPs. The alteration of the matrix
architecture may have profound secondary effects on
cellular proliferation, morphology and migration. In
addition, the MMPs may modulate the wound milieu by
their effect on the rate of degradation of growth factors,
cytokines and their receptors (1).

Table 2. Profile of selected cytokines in wound healing.

Cytokine

Physiological effects

Clinical and experimental correlates

TNF α
Tumour necrosis factor α

•
•
•
•
•
•
•

Leucocyte chemotaxis
Monocyte maturation
Macrophage activation
Inhibits fibroplasia
Stimulates IL-6 by fibroblasts
Increases activity of MMP-2 and MMP-9
Potentiates VEGF production

Elevated levels linked to insufficient
collagen deposition and poor healing

Interleukin-1

•
•
•
•
•

Leucocyte and fibroblast chemotaxis
Macrophage activation
Angiogenic
Stimulates fibroblast MMP production
Stimulates keratinocyte migration

High levels associated with delayed healing

Interleukin-6

• Inhibits extracellular matrix breakdown
• Stimulates fibroblasts to secrete TIMP

High levels associated with poor healing
Peaks at 24 h

Interleukin-8

•
•
•
•
•

Parallels IL-6, peaking at 24 h

Interleukin-4 and Interleukin-10
(The anti-inflammatory interleukins)

• Inhibit leucocyte chemotaxis
• Downregulate expression of many pro-inflammatory
cytokines

IL-10 exhibits bimodal wound levels
peaking at 3 h and 72 h

Interferons
(The antifibrogenic cytokines)

• Inhibitory to fibroblasts
• Inhibit post-translational changes to collagen
• Increase collagenase activity

IFN γ reduces keloid
administered intradermally

Leukocyte chemotaxis
Enhances epithelialisation
Keratinocyte migration
Upregulates plasminogen activator in keratinocytes
Inhibits fibroblast induced contraction of collagen

Levels high in chronic nonhealing wounds

size

when
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The activity of the MMPs is counterbalanced by tissue
inhibitors of MMPs (TIMPs) which bind to the MMPs,
inactivating them (2). TIMPs may also independently
stimulate or inhibit cellular proliferation and act to inhibit
angiogenesis (2,3). Other inhibitors include α2
macroglobulin, which serves as the predominant
antiprotease immediately after wounding.
Realisation of the importance of this proteaseantiprotease balance has opened new avenues amenable
to intervention in an effort to improve wound outcomes.
Examples include Promogran ®, a dressing consisting of
collagen and oxidised regenerated celulose that seeks to
mop up and inactivate the MMPs in the wound, and the
possibility of manipulating the protease content in a
wound by gene therapy.
Adhesion molecules
Adhesion, at a molecular level between cells and
between cells and the matrix, is a vital physical process
which initiates and modulates many chemical and
biological effects. Adhesion is accomplished by a large
family of adhesion molecules which are transmembrane
proteins that serve as lines of communication between
the internal processes of the cell and its exterior. There
are currently 6 recognised superfamilies of adhesion
molecules – the immunoglobulin-like superfamily, the
cadherins, the integrins, the receptor protein tyrosine
phosphatases, the selectins and the hyaluronate
receptors. The 3 illustrative examples which follow
outline how indispensable these ubiquitous recognition
molecules are to the process of wound healing.
Platelet aggregation and leucocyte margination in the
capillaries, one of the earliest steps in the inflammatory
phase of wound healing, is dependent on the expression
of selectins and integrins.
Keratinocyte migration is an important step in reepithelialisation . Migrating keratinocytes overexpress a
set of integrins which engage molecules like fibronectin
and vitronectin in the blood clot and matrix to provide
them a foothold as they edge forward.
Adhesion molecules may also be shed by endothelial
cells at the direction of cytokines released by activated
leucocytes. Soluble E selectin and soluble VCAM-1
(vascular cell adhesion molecule-1) shed in this manner
adhere to adjacent endothelial cells and exert a direct
angiogenic effect (4).
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Advances from a clinical perspective
Moist wound healing
Ever since Winter’s studies (5-7) highlighted the
importance of a moist wound environment, there has
been a growing body of evidence lending it support. The
concept of maintaining a moist wound environment has
sparked the so-called “dressing revolution” with a wide
spectrum of moisture-retaining and semi-occlusive
dressings flooding the market.
A moist wound environment is claimed to have the
following advantages:
1. It prevents tissue dehydration, which helps to
preserve the viability and proliferative potential of the
cells. This is associated with earlier epithelialisation.
2. Accelerates angiogenesis.
3. Increases breakdown of dead tissue and fibrin
contributing to autolytic debridement.
4. Potentiates interaction of growth factors with their
target cells.
5. Reduces the incidence of infection.
6. Is associated with less pain.
In the contrast, exposure of the wound to air causes
wound dessication and scabbing, which delay
epithelialisation. The healing time of superficial and deep
cutaneous wounds has been shown to be faster and less
painful when treated with a moisture- retaining dressing
as against a simple gauze dressing (8-10).
Wound bed preparation
Wound bed preparation is a concept which attempts
to systematize the management of the chronic wound
with a view to accelerate endogenous healing and to
facilitate the effectiveness of other therapeutic measures.
The 3 pillars of wound bed preparation are management
of necrotic burden by debridement, managing bacterial
burden and maintaining moisture balance. Additional and
related goals include correcting cellular dysfunction and
achieving biochemical balance.
Debridement could be achieved
mechanical or enzymatic means.

by

surgical,

Mechanical debridement refers to a range of
techniques like wet-to-dry dressings, which cause
separation of eschar and its removal with the dressing;
wound irrigation, which ideally is irrigation of the wound
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by saline using a 20 gauge catheter at 15 pounds per
square inch of pressure; and whirlpool or foot soaks in
medicated saline to remove debris. Enzymatic
debridement refers to the topical use of bacterial
collagenase, DNAse/fibrinolysin, papain/urea combination
or trypsin to achieve clearance of debris.
Bacterial burden may be reduced by a combination of
debridement; correcting underlying causes like ischaemia
and immunosuppression, and topical antiseptics delivered
through dressings like cadexomer iodine and silver based
dressings.
Maintaining moisture balance involves the control of
exudate while maintaining a moist wound environment
that is conducive to healing. Exudate may be controlled
using specially designed absorbent dressings or
mechanical devices such as topical negative pressure
therapy. Moisture-retaining dressings like hydrogels,
hydrocolloids and foams aid in maintaining a balance and
preventing dessication.
Though the individual components mentioned above
are not entirely new, the concept of wound bed
preparation has unified the different approaches, giving
clinicians a global perspective of the problem facing them
at the wound bed while at the same time stressing the
importance of each of the components.
Advances in the assessment and investigation of
wounds
Wound assessment has several dimensions– clinical,
physical, physiological, biochemical, histological and
genetic. While advanced techniques employed in wound
healing research like cytological, immunohistochemical
and molecular methods have made significant
contributions to our understanding, only those of
immediate relevance to the practicing clinician are
considered here.
Scoring and Grading: Wounds are heterogeneous not
only in terms of aetiology but also in quantitative (size,
shape) and qualitative terms (wound bed, slough,
discharge, effects produced etc). Over the years scoring
and grading systems have been designed to objectively
assess the wound to minimise inter-observer variation.
Scoring or grading wounds also helps in classifying
wounds and to an extent provides prognostic
information. Uniformity in reporting allows for
comparisons amongst and between various wounds as
well as following the progress of a wound over time.

Some systems like those used for assessing pressure
ulcers are useful in day to day practice. Others, like the
ASEPSIS score (11) and the Southampton grading system
(12) pertaining to postoperative wounds, are useful tools
that are mainly employed in the research setting. Because
of the heterogeneity of the wounds, to date there is no
single acceptable system that could be adopted universally
to assess all wounds.
Infection: Wound infection has been and continues to
be an elusive term to define and reach a consensus on.
One systematic review (13) addressing the quality of
measurement of surgical wound infection identified 41
different definitions of wound infection in the 90
prospective studies included in the analysis. This aside,
attempts to correlate clinical signs and symptoms with
wound infection have met with some success. Cutting and
Harding (14) identified friable bright red granulation,
exuberant granulation, increased discharge and new areas
of slough at the wound base as possible signs of infection.
Gardner et al. (15) validated pain, increasing wound size,
new areas of breakdown and odour as signs with a high
5
correlation with > 10 colony forming organisms per
gram of tissue. Grayson et al. (16) validated the exposure
of or probing to bone in diabetic foot ulcers as a useful
bedside test for deep infection with a specificity of 85%
and positive predictive value of 89%.
Quantitation of bacterial load in a wound by tissue
biopsy is expensive and time consuming. A
semiquantitaive swab technique has been proposed as an
alternative. The wound is first swabbed after the bed is
cleaned with saline. The swab is then used to streak 4
quadrants of a solid medium sequentially. A growth in the
fourth quadrant of > 30 colony forming units has been
5
correlated with a bacterial burden of > 10 organisms
per gram of tissue (17).
Biochemical assessment: Advances in technology
have made measurement of cytokines, growth factors
and proteases possible. Wound fluid and biopsy
specimens of wounds have been the tools of investigation
with respect to these factors.
The pro-inflammatory cytokine content and protease
content of chronic wounds has been observed to be
higher than in acute healing wounds. The levels of TNF α
and IL-1 remain elevated in chronic wounds (18,19).
Chronic wounds also tend to have a lower growth factor
content.
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The protease-antiprotease balance seems to be critical
and a close correlation between the high ratios of
TIMP/MMP-9 and healing of pressure ulcers has been
noted (20). Wounds that are healing normally show a
peak MMP-9 level at 24 h which declines significantly by
48 h. Persistent elevation of MMP-9 in wound fluid has
been shown to be a useful marker of delayed healing.
Absence of a decline in MMP-9 between 24 and 48 h in
postoperative wounds has been correlated with infection
and chronicity of wounds (21).
Though currently wound fluid analysis remains largely
a research tool, in future it may evolve further as a source
of vital prognostic wound information or may even be
useful in directing therapy.
Developments in therapy
Physical methods
Topical negative pressure therapy (TNP)
Pioneered by Fleischmann et al. (22) and Morykwas
and Argenta (23) in the mid 90s, TNP involves the
application of an external sub-atmospheric pressure to
exert a suction force across the wound. Vacuum assisted
closure (VAC), sub-atmospheric pressure dressing (SPD),
vacuum sealing technique (VST), sealed surface wound
suction (SSS), and negative pressure therapy (NPT) are
alternative terminologies.
The wound is compartmentalised by an airtight seal
around it and through a dressing interface (which is
usually a polyurethane or polyvinyl alcohol foam) the
compartment is connected to an external suction
apparatus. The application of pressure may be continuous
or intermittent. Pressures used range between -125 and
-175 mmHg. Dressings are usually changed every 48-72
h.
TNP has been shown to increase dermal perfusion,
stimulate granulation tissue, decrease interstitial fluid,
control wound exudate and decrease bacterial load.
These effects have clinically translated to better
healing rates of wounds in a variety of specialities
including plastic, cardiothoracic and orthopaedic surgery.
The clinical indications of TNP are ever expanding – from
ulcers and burns to wound dehiscences and fistulae. Other
useful roles are as an adjunct in tissue salvage in
reconstructive surgery, burns and trauma where the
application of TNP has had the effect of preserving the
vitality of tissues and flaps of borderline viability. In
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reconstructive surgery, the ability of TNP in reducing the
size of a tissue defect, which has been termed ‘the
reverse expansion effect’, has been exploited to enable
downgrading of the wound on the reconstructive ladder
so that a simpler procedure (for example, secondary
suture) may be used instead of a more complex one (such
as a local flap).
Problems with TNP include pain, fluid loss especially
in large wounds and risk of bleeding. Large controlled
trials which are underway will hopefully define its precise
role in the therapeutic armamentarium of the wound care
provider.
Warming (therapeutic heat)
Although the application of warmth to wounds in the
form of compresses is a well known practice since time
immemorial, the primary objective had been pain relief.
The science behind the beneficial effects of heat on tissues
has only been explored relatively recently. Although peroperative warming is now standard anaesthetic practice,
the application of warming as a modality to reduce wound
infection and to augment wound healing is a novel
approach which holds promise.
The following facts are now established
• Warming improves blood flow and oxygen tension
in tissues (24,25)
• Warming decreases the rate of wound infection in
clean elective surgery (26)
• Warming reduces the risk of developing pressure
ulcers (27)
• Warming may eradicate established MRSA infection
in pressure sores (28)
Warming may be applied systemically or locally.
Systemic warming is usually done using specially designed
warming blankets (Bair-Hugger, Arizant Health Care) or
mattresses (Pegasus-Inditherm mattresses). The
mechanisms used include circulating warm air/water or
electrically powered coils. Local warming is applied using
specially designed pads which may use an external source
of electricity (Warm up dressing, Augustine Medical Inc.)
or an exothermic reaction triggered by exposure to
oxygen.
The ideal duration and intensity of heat needed for
optimising the wound milieu is yet to be determined.
Warming is attractive as an option for many reasons:
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1. It can be applied prophylactically as well as
therapeutically.
2. Is simple to apply (systemically or locally) and well
tolerated.
3. Is cheap and cost effective.
4. May help to reduce the use of antibiotics.
5. May be useful in circumstances where antibiotics
fail.
Electrical stimulation
Research into the effects of electricity on living tissues
has unravelled the pivotal role of electrical charge in
interactions in biological systems both at cellular and
molecular level. Electricity-induced tissue hyperaemia and
galvanotaxis, the purposeful predictable movement of
cells under the influence of electricity, are well
documented. However, only over the past couple of
decades has electrical stimulation made the slow
transition from the realms of research to the clinical
arena.
The devices used to deliver the current are
heterogeneous in terms of the type of current, voltage,
intensity and waveforms used. Gardner et al. in a metaanalysis reviewed the effect of electrical stimulation in
healing chronic wounds (29). Of the 14 studies included,
9 were randomised controlled trials. The primary
outcome measure was the mean percentage area of the
wound healed per week. There were 591 ulcers in the
electrical stimulation group and 212 in the control group.
The mean percentage area of the wound healed per week
in the ES group was 22.5% compared to 9% in the
control group. Pressure ulcers had the greatest response.
Further research is needed to define the optimum
dose-response and the relative effectiveness of the
different modalities of electrical stimulation.
4. Miscellaneous physical methods
Magnetism, laser phototherapy, cycloidal vibration
therapy and ultrasound are some of the other physical
modalities which have been observed to have beneficial
effects on various steps of the wound healing cascade,
both in the laboratory and in the clinic. However, most of
the evidence to date has been in the form of observational
studies with very few controlled trials employing small
numbers of patients. Magnetism in particular was more
effective than control in healing plantar ulcers in leprosy
(30) and resulted in better wound outcomes in patients

after liposuction (31). Large well powered, blinded,
randomised controlled trials are needed before the clinical
role of these modalities can be judged.
B. Biological Therapy
1. Larva therapy
Although conceptually many centuries old, larva
therapy in its current form was ‘rediscovered’ in the late
1980s and was given a fresh breath of life by the work
of Sherman (32) in the US and popularised in the UK by
the biological research unit at Bridgend in Wales.
Also termed maggot therapy and biosurgery, it
involves the application onto the wound of necrophagous
larvae of the green bottle fly Lucilia Sericata, reared in a
controlled and sterile environment.
Maggots augment wound healing by a number of
mechanisms:
• Antimicrobial effect: Larvae ingest and kill bacteria
and may secrete chemicals with antimicrobial
action. The larval secretions increase the pH of the
wound to 8-8.5, which has an inhibitory effect on
certain bacteria.
• Selective debridement: Several proteases capable of
degrading many matrix components have been
characterised in their secretions, which cause rapid
and selective debridement of dead tissue (33,34).
• Promotion of tissue interactions: Larval secretions
favourably influence the fibroblast to extracellular
matrix interactions, which is critical in many
processes in wound healing. Secretions by
removing the fibrin cuff might kick- start the
healing process in a static chronic wound (32-34).
The larvae are 1-2 mm in size and do not multiply in
the wound. The recommended dose of larvae is 10 larvae
per square centimetre of wound. Usually 1-2 applications
achieve adequate debridement. The dressing, which is left
in place for 2-3 days, needs to be oxygen-permeable and
provide a moist environment. Larva therapy is best suited
for wounds with slough and infection and has been shown
to be useful in diabetic ulcers, pressure sores and venous
ulcers. It can be a useful tool against drug resistant
strains of bacteria, for example Methicillin resistant
Staphylococcus aureus (MRSA). Larva therapy is cost
effective and tolerance is excellent. Apart from the
presence of fistulas, and the proximity of the wound to
major blood vessels or vital organs, there appear to be no
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contraindications. Limitations are the lack of aesthetic
appeal and the short shelf-life of maggots.
2. Skin Substitutes
That “skin is the best dressing” is a well known
surgical aphorism. The normal structural and cellular
components of skin not only have a barrier function on
the wound but also exert a complex, benign and active
influence on the wound environment which has been
termed the biological effect of a skin dressing.
Tissue engineering has provided us with a number of
clinically viable alternatives to autograft skin that may be
used in a broad spectrum of clinical scenarios – from
covering raw areas as in burns to stimulating the healing
processes in a static chronic wound. The products may be
classified into single layered products (containing the
equivalent of either the epidermis or the dermis) or
bilayered products (containing layers which mimic both
the dermis and epidermis). A brief discussion on a few of
the currently available products follows.
Single layered products
A. Cultured keratinocytes (Epicel ® , Genzyme
biosurgery)
Keratinocytes harvested from the host can be grown
to produce stratified sheets of keratinocytes in vitro. The
major advantage of this technique is that only a 2-8 cm2
area of the host skin is needed to generate sheets of
autologous keratinocytes which can cover 60-90% of the
patients’ surface area. Expansion of the order of 1001000 -fold is possible in 2-4 weeks. The main use of
keratinocyte sheets has been as a method of achieving
early wound closure in extensive burns. It has also been
applied over allogenic cryopreserved graft skin in this
situation. Long term survival of keratinocytes has not
been proven, but at least it functions as a moist occlusive
dressing and stimulates endogenous healing by
generating cytokines and growth factors (35).
B. Human dermal replacement (Dermagraft®,
Smith and Nephew Inc.)
New- born foreskin derived fibroblasts when cultured
on a 3-dimensional polymer scaffold remain metabolically
active, producing growth factors that support wound
healing. Dermagraft is single layered and cryopreserved.
The polymer scaffold is absorbable. It has been used in
burns and diabetic foot ulcers.
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C. Cadaver derived processed dermis (Alloderm®,
Life Cell Corporation)
Cadaveric skin is processed to remove all dermal and
epidermal cells, resulting in an acellular dermal collagen
matrix. Following application the graft revascularises
from the wound bed and is repopulated by recipient cells.
Bilayered Products
D. Bilayered
Organogenesis Inc.)

skin

equivalent

(Apligraf ® ,

Bioengineered bilayered skin substitutes contain a
dermal and epidermal layer closely resembling the
architecture of skin. They contain matrix proteins and
expresses cytokines. They do not, however, contain
melanocytes,
Langerhans
cells,
macrophages,
lymphocytes, blood vessels or appendages. Apligraf® is
one such substitute which contains neonatal foreskin
fibroblasts and keratinocytes on a dermal matrix made of
bovine type I collagen. It has been proven to be effective
in achieving faster healing in diabetic and venous and
pressure ulcers when compared to conventional
treatment (36-39). An infected wound and allergy to
bovine products are contraindications.
E. TransCyte® (Smith and Nephew Inc.)
This biological dressing contains human neonatal
fibroblasts cultured on the silicone membrane bonded
nylon mesh. This has been successfully used in treating
partial thickness burn wounds (40).

F. Integra® (Integra Life Sciences)
The dermal equivalent of this bilayered substitute is
made of cross linked bovine collagen and chondroitin
sulphate. The epidermal equivalent is made of silicone. As
healing progresses, the dermal layer is replaced by an
endogenous matrix. The silicone layer may then be
removed and an epidermal autograft applied.
3. Stem cell therapy
Bone marrow derived stem cells are pleuripotent,
being capable of differentiating into a variety of cells. This
property is being exploited in the wound healing
environment. Early reports from case series on the
application of bone marrow derived cells on the chronic
wound are promising (41). However, large controlled
trials are needed to clarify their role in therapeutics.
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4. Growth factors
Normal wound healing is heavily dependent on a
plethora of growth factors and cytokines which variably
interact with cells and the matrix at different stages. Use
of growth factors topically to augment wound healing,
although a very intuitive prospect, is fraught with
difficulties for the following reasons:
• The multitude of factors involved
• Problems in matching the spatial and temporal
profile found in wounds
• Rapid degradation in the wound by proteases
• Lack of a vehicle for sustained release
• Cost
Although animal studies have evaluated a number of
growth factors, only the following have shown promise in
clinical studies.
• Platelet derived growth factor (PDGF)
PDGF is currently the only growth factor licensed for
topical use. The efficacy of recombinant PDGF-BB
(becaplermin gel) in diabetic foot ulcers has been proven
in a number of randomised trials (42,43). In a metaanalysis of 4 randomised controlled trials, patients with a
2
median ulcer area of 1.5 cm treated with becaplermin
gel at a concentration of 100 µg/g, achieved a 39%
higher healing rate when compared to placebo gel (44).
Efficacy of PDGF in healing pressure ulcers has been
demonstrated in phase I and II human studies (45,46).
• Keratinocyte growth factor 2 (KGF 2)
A multicentric double blind controlled study using
recombinant KGF-2 (Repifermin) on venous ulcers
showed that it healed twice the number of ulcers and at
twice the rate of controls in 12 weeks (47).
• EGF and FGF
EGF and basic FGF have been used topically to
augment epithelialisation of skin donor sites.
Improvements in healing have, however, been negligible
to modest (48-50).
While some studies found EGF to be effective in nonhealing chronic wounds (51), diabetic foot ulcers (52) and
in corneal wounds (53), Falanga did not detect any
significant improvement in venous ulcers (54).
FGF has proved useful when applied to pressure sores
(55).

5. Gene therapy
Gene therapy, put simply, aims to help the cell to help
itself by providing it with specific genes. Genes once
incorporated in the cell affect the cell and its milieu
through their products of expression. These in the
context of wound healing are growth factors, their
receptors, adhesion molecules and inhibitors of
proteases. Gene therapy has the potential to circumvent
most of the shortcomings of topical growth factor
therapy mentioned above.
Classical gene therapy involves incorporating the gene
to directly influence the wound by its product of
expression. Epigenetic therapy is a variation wherein a
nucleotide sequence is used to modulate the expression of
the endogenous genes.
Genes can be delivered by biological (viral vectors),
physical (e.g., microinjection, microseeding), and chemical
(e.g., cationic liposomes) methods. A new method of
sustained delivery of genes to the wound milieu called
matrix–enabled gene transfer or gene activated matrix
(GAM) therapy is evolving. This involves embedding genes
onto a scaffold matrix which remains in the wound
increasing the length of exposure of target cells to the
genes (56).
Transfer could be established in vivo (the gene being
delivered to the cells in the wound directly) or ex vivo
(gene transfection is achieved outside the wound
environment in a selected population of cells which are
then transplanted into the wound).
Once in the wound environment, the genes may also
be controlled by externally applied substances by specific
mechanisms termed genetic switches.
The scope of gene therapy is expanding:
Genes may be employed to augment an effect – (e.g.,
promote healing)
- Genes for growth factors and their receptors
- Genes for tissue inhibitors of metalloproteinases
Alternatively they may be used to inhibit an effect
(e.g., suppress overhealing or excessive scarring)
- Genes for antibodies against specific growth factors
- Genes for soluble receptors of growth factors
Gene therapy as applied to wound healing is
understandably in its infancy. Currently trials are
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underway exploring the use of PDGF, VEGF and FGF
genes in diabetic foot and venous ulcers.
Future directions include using multiple genes
concurrently (e.g., genes for growth factors and their
receptors), and fine tuning the gene expression as
required using genetic switches.
6. Other biological therapies
Fibrin sealant, primarily used for its adhesive and
haemostatic properties, has been claimed to accelerate
revascularisation, decrease wound contraction and
produce less inflammatory response when compared to
sutures. It has also been used as a vehicle for delivery of
growth factors. However, its use in chronic non-healing
wounds is limited.
Platelet gel prepared from autologous blood contains
supraphysiological doses of platelets which provide growth
factors and proteins like fibronectin. In the field of
maxillofacial surgery they have been found to reduce
oedema and ecchymosis in the early postoperative phase
and to accelerate the ingrowth of autogenous bone grafts.
However, a randomised trial of its effect on venous ulcers
did not find any significant effect on healing (57).
C. Miscellaneous Therapies
1. Hyperbaric oxygen
Oxygen is more than a nutrient. Most vital cellular and
molecular mechanisms are influenced either directly or
indirectly by the available tissue levels of oxygen. Well
known impediments to healing like ischaemia act so
because of the tissue hypoxia they impose, whereas the
beneficial effects of modalities like warming are at least
in part attributable to enhancement of tissue
oxygenation. Hyperbaric oxygen therapy is one method of
increasing oxygen delivery to tissues and involves
breathing 100% oxygen in pressurised chambers (2-2.5
atmospheres). The PO2 may reach 1500 mmHg.
A recent systematic review (58) on the use of
hyperbaric oxygen in wounds identified 6 controlled trials
(2 of which were randomised) involving diabetic ulcers
and 1 non-randomised trial involving chronic non-healing
wounds. All of these studies reported statistically
significant positive clinical outcomes in favour of
hyperbaric oxygen therapy.
Hyperbaric oxygen therapy needs special equipment
and expertise and is not without complications. This
restricts its use as an adjunct in recalcitrant ulcers.
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2. Dressings
The sheer variety of dressings available today is
probably matched only by the diversity in the wounds
they are employed to treat. Practices steeped in tradition
like the simple gauze soaked in antiseptics applied directly
to the open wound have given way to more evidencebased approaches aimed at maintaining a moist
environment that supports the healing wound. Another
conceptual shift is targeted therapy. The appreciation that
wounds have different barriers to healing at different
points in time has guided the evolution of the various
groups of dressings addressing specific problems. The
choice of dressing is dictated by the needs of the wound
and this is reflected in the classification system shown in
Table 3.
However, this classification is not a rigid one as, in
practice, there are many hybrid or composite dressings
which combine aspects of members of different groups to
achieve an optimum effect. A brief discussion on some of
the types of dressings follows.
• Films are usually polyurethane based, transparent
allowing inspection, retain moisture, provide
occlusion, prevent contamination but provide no
absorption. Typical use includes the postoperative
wound.
• Soft silicone mesh (Mepitel*) is a non-adherent,
porous, semi-transparent dressing with a wound
contact layer consisting of a flexible polyamide net
coated with soft silicone. Although it is nonabsorbant, the porous nature allows fluid to pass
through to the secondary dressing. Primarily used
in skin donor areas.
• Hydrocolloids are composed of a mixture of
adhesive, absorptive (carboxymethyl cellulose) and
elastomeric ingredients. They are waterproof,
impermeable to bacteria, promote autolytic
debridement and can be changed once every 3-7
days. However, absorption is limited. Useful in
granulating and epithelialising wounds with
minimal exudates.
• Hydrogels are composed of a polymer
(carboxymethyl cellulose or modified starch),
propylene glycol and up to 80% water. Their main
use is as hydrating agents in drying wounds. They
promote autolytic debridement but absorption is
limited.
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Table 3. Types of Dressings.
Broad category

Primary goal

Group

Examples /Comments

General
purpose dressings

1. Cover with varying occlusion

Augmented Fabrics Films
Aerosols/Sprays

Mepitel*, Vaseline gauze, tulle
Opsite*, Tegaderm*, Opsite*

2. Occlusion, Absorption,
Hydration

Foams

Allevyn*, Lyofoam*

Hydrogels

Intrasite*, Tegagel*

Hydrocolloids

Duoderm*,Comfeel*, Tegasorb*

Alginates

Sorbsan*, Kaltostat*

Medicated dressings

Iodine, silver, zinc and antibiotics can be delivered
by a variety of vehicles-ointments/creams/
impregnated beads

Nitric oxide releasing dressings

Experimental

Cell platforms

Experimental. Being developed to enable cell based
therapy

Gene activated matrix

Experimental. Being developed to deliver genes
effectively

Specialised dressings

3. Delivery

4. Tissue substitution
5. Deodorisation

Skin substitutes
Adsorbant and antibiotic
impregnated types

6. Protease sequestration

7. Compression

Epicel*, Demagraft*
Charcoal based dressings, Inadine* , Polysaccharide
beads
Promogran*
Modified dialdehyde cotton gauze

Three and four layered bandages Tensopress*, Coban*

• Alginates are derived from seaweed and are
available as ropes, sheets or wafers. Are highly
absorbent and convert to a gel on absorption.
However, if the wound is not producing enough
fluid, they may cause drying of the wound. Useful
in packing cavities, but usually require a secondary
dressing.

• Promogran* is a protease modulating matrix
dressing made of collagen and oxidised
regenerated cellulose. Promogran binds proteases
which, when present in excess, are a major barrier
to healing. This also results in the increased
availability of growth factors in the wound.
Promogran has been found to be useful in venous
and diabetic ulcers.

• Foams are polyurethane based, non-adherent,
heavily absorbent dressings which conform to
wound contours and can be left in place for up to
4 days. However, they do not protect from
external contamination and usually need a
secondary dressing. Useful in wounds with large
volume exudates.

• Modified dialdehyde cotton gauze is ordinary
cotton
gauze
modified
by
oxidation,
phosphorylation and sulphonation; it has been
shown in in vitro studies to have a 4-fold affinity
to sequestrate neutrophil elastase (59). The
technology although promising needs to be tested
in the clinical setting.
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• Cell platform is an evolving method of delivering
cell based therapy to the wound. Keratinocytes
and fibroblasts grown on bioreactive microporous
beads enclosed in a polyethylene bag have shown
potential when applied to wounds in mice (60).

Conclusion
The healing wound has been recognised for millennia
as a minefield of activity– an activity which we now know
is orchestrated by native and infiltrating cells interacting
with the matrix. The language of this complex machinery
is only beginning to be uncovered by the discovery of
many superfamilies of molecules. Defining the
interactions precisely in space and time are the challenges
for the future. Developments in therapy would be
expected to follow naturally.

multidisciplinary, may evolve into a specialty in its own
right. However, wounds, as ubiquitous as they are, will
continue to be seen and treated by different strata of
health care providers. This means that while technologies
like tissue engineering and gene therapy hold great
potential it is the appreciation of the pathophysiology of
wounds along with the awareness of the different
modalities of treatment from which to choose which will
have the greatest impact on the average patient. This
article seeks to address that need for dissemination.

Corresponding autor:
Senthil KUMAR
9, Middlefield road
Hardwick
Stockton-on-Tees
United Kingdom
TS19 8PF
e-mail: sanskrity@hotmail.com

From a clinical standpoint it is tempting to speculate
that wound management, which is increasingly becoming
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